A Dose Escalation Study of PF-06939999 in Participants With Advanced or Metastatic Solid
Tumors. A Phase 1 Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of
Escalating Doses of PF-06939999 (PRMT5 Inhibitor) in Participants With Advanced or Metastatic
Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Esophageal Cancer,
Endometrial Cancer, Cervical Cancer and Bladder Cancer.